Moreover, in a subanalysis of the EMILIA trial (NCT00829166) [29], HER2 mRNA analysis by quantitative reverse transcriptase-polymerase chain reaction and the PIK3CA mutational status were analyzed on tumor tissues. This evidence concerns the gene ERBB2 and neoplasm.